热门资讯> 正文
Rapport Therapeutics报告第四季度业绩
2025-03-11 21:41
- Rapport Therapeutics press release (NASDAQ:RAPP): Q4 Net Loss for the fourth quarter of 2024 was $20.0 million, as compared to $13.5 million for the prior year period.
- The Company ended the fourth quarter with $305.3 million in cash, cash equivalents and short-term investments, compared to $320.7 million as of September 30, 2024.
More on Rapport Therapeutics
- Historical earnings data for Rapport Therapeutics
- Financial information for Rapport Therapeutics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。